Accès gratuit
Numéro
Med Sci (Paris)
Volume 32, Numéro 3, Mars 2016
Page(s) 290 - 296
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20163203014
Publié en ligne 23 mars 2016
  1. Junt T, Schulze H, Chen Z, et al. Dynamic visualization of thrombopoiesis within bone marrow. Science 2007 ; 317 : 1767–1770. [CrossRef] [PubMed]
  2. Patel SR, Richardson JL, Schulze H, et al. Differential roles of microtubule assembly and sliding in proplatelet formation by megakaryocytes. Blood 2005 ; 106 : 4076–4085. [CrossRef] [PubMed]
  3. Italiano JE, Jr, Lecine P, Shivdasani RA, Hartwig JH. Blood platelets are assembled principally at the ends of proplatelet processes produced by differentiated megakaryocytes. J Cell Biol 1999 ; 147 : 1299–1312. [CrossRef] [PubMed]
  4. Leven RM. Megakaryocyte motility and platelet formation. Scanning Microsc 1987 ; 1 : 1701–1709. [PubMed]
  5. Andrews RK, Berndt MC. Platelet physiology and thrombosis. Thromb Res 2004 ; 114 : 447–453. [CrossRef] [PubMed]
  6. Liddington RC. Structural aspects of integrins. Adv Exp Med Biol 2014 ; 819 : 111–126. [CrossRef] [PubMed]
  7. Rybarczyk BJ, Lawrence SO, Simpson-Haidaris PJ. Matrix-fibrinogen enhances wound closure by increasing both cell proliferation and migration. Blood 2003 ; 102 : 4035–4043. [CrossRef] [PubMed]
  8. Danen EH, Sonnenberg A. Integrins in regulation of tissue development and function. J Pathol 2003 ; 201 : 632–641. [CrossRef] [PubMed]
  9. Stupack DG, Cheresh DA. Apoptotic cues from the extracellular matrix: regulators of angiogenesis. Oncogene 2003 ; 22 : 9022–9029. [CrossRef] [PubMed]
  10. Ceze N, Lecomte T, Watier H. Anticorps monoclonaux thérapeutiques et ciblage vasculaire. Med Sci (Paris) 2009 ; 25 : 1099–1104. [CrossRef] [EDP Sciences] [PubMed]
  11. Jin H, Varner J. Integrins: roles in cancer development and as treatment targets. Br J Cancer 2004 ; 90 : 561–565. [CrossRef] [PubMed]
  12. Wehrle-Haller B, Imhof BA. Integrin-dependent pathologies. J Pathol 2003 ; 200 : 481–487. [CrossRef] [PubMed]
  13. Jackson SP, Nesbitt WS, Kulkarni S. Signaling events underlying thrombus formation. J Thromb Haemost 2003 ; 1 : 1602–1612. [CrossRef] [PubMed]
  14. Xiong JP, Stehle T, Diefenbach B, et al. Crystal structure of the extracellular segment of integrin alpha Vbeta3. Science 2001 ; 294 : 339–345. [CrossRef] [PubMed]
  15. Gottschalk KE. A coiled-coil structure of the alphaIIbbeta3 integrin transmembrane and cytoplasmic domains in its resting state. Structure 2005 ; 13 : 703–712. [CrossRef] [PubMed]
  16. Wegener KL, Campbell ID. Transmembrane and cytoplasmic domains in integrin activation and protein-protein interactions (review). Mol Membr Biol 2008 ; 25 : 376–387. [CrossRef] [PubMed]
  17. Fiore M, Nurden AT, Nurden P, Seligsohn U. Clinical utility gene card for: Glanzmann thrombasthenia. Eur J Hum Genet 2012 ; 20 : 1102. [CrossRef]
  18. Nurden AT. Inherited abnormalities of platelets. Thromb Haemost 1999 ; 82 : 468–480. [PubMed]
  19. Nurden AT, Pillois X, Fiore M, et al. Expanding the mutation spectrum affecting alphaIIbbeta3 iIntegrin in Glanzmann thrombasthenia: screening of the ITGA2B and ITGB3 genes in a large international cohort. Hum Mutat 2015 ; 36 : 548–561. [CrossRef] [PubMed]
  20. Hardisty R, Pidard D, Cox A, et al. A defect of platelet aggregation associated with an abnormal distribution of glycoprotein IIb-IIIa complexes within the platelet: the cause of a lifelong bleeding disorder. Blood 1992 ; 80 : 696–708. [PubMed]
  21. Peyruchaud O, Nurden AT, Milet S, et al. R to Q amino acid substitution in the GFFKR sequence of the cytoplasmic domain of the integrin IIb subunit in a patient with a Glanzmann’s thrombasthenia-like syndrome. Blood 1998 ; 92 : 4178–4187. [PubMed]
  22. Ghevaert C, Salsmann A, Watkins NA, et al. A nonsynonymous SNP in the ITGB3 gene disrupts the conserved membrane-proximal cytoplasmic salt bridge in the alphaIIbbeta3 integrin and cosegregates dominantly with abnormal proplatelet formation and macrothrombocytopenia. Blood 2008 ; 111 : 3407–3414. [CrossRef] [PubMed]
  23. Kashiwagi H, Kunishima S, Kiyomizu K, et al. Demonstration of novel gain-of-function mutations of alphaIIbbeta3: association with macrothrombocytopenia and glanzmann thrombasthenia-like phenotype. Mol Genet Genomic Med 2013 ; 1 : 77–86. [CrossRef] [PubMed]
  24. Gresele P, Falcinelli E, Giannini S, et al. Dominant inheritance of a novel integrin beta3 mutation associated with a hereditary macrothrombocytopenia and platelet dysfunction in two Italian families. Haematologica 2009 ; 94 : 663–669. [CrossRef] [PubMed]
  25. Kunishima S, Kashiwagi H, Otsu M, et al. Heterozygous ITGA2B R995W mutation inducing constitutive activation of the alphaIIbbeta3 receptor affects proplatelet formation and causes congenital macrothrombocytopenia. Blood 2011 ; 117 : 5479–5484. [CrossRef] [PubMed]
  26. Kobayashi Y, Matsui H, Kanai A, et al. Identification of the integrin beta3 L718P mutation in a pedigree with autosomal dominant thrombocytopenia with anisocytosis. Br J Haematol 2013 ; 160 : 521–529. [CrossRef]
  27. Wu Y, Span LM, Nygren P, et al. The tyrosine kinase c-Src specifically binds to the active integrin alphaIIbbeta3 to initiate outside-in signaling in platelets. J Biol Chem 2015 ; 290 : 15825–15834. [CrossRef] [PubMed]
  28. Bury L, Malara A, Gresele P, Balduini A. Outside-in signalling generated by a constitutively activated integrin alphaIIbbeta3 impairs proplatelet formation in human megakaryocytes. PLoS One 2012 ; 7 : e34449. [CrossRef] [PubMed]
  29. Primeau M, Lamarche-Vane N. Coup d’œil sur les petites GTPases Rho. Med Sci (Paris) 2008 ; 24 : 157–162. [CrossRef] [EDP Sciences] [PubMed]
  30. Chang Y, Aurade F, Larbret F, et al. Proplatelet formation is regulated by the Rho/ROCK pathway. Blood 2007 ; 109 : 4229–4236. [CrossRef] [PubMed]
  31. Schaffner-Reckinger E, Salsmann A, Debili N, et al. Overexpression of the partially activated alpha(IIb)beta3D723H integrin salt bridge mutant downregulates RhoA activity and induces microtubule-dependent proplatelet-like extensions in Chinese hamster ovary cells. J Thromb Haemost 2009 ; 7 : 1207–1217. [CrossRef] [PubMed]
  32. McMillan R, Wang L, Tomer A, et al. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood 2004 ; 103 : 1364–1369. [CrossRef] [PubMed]
  33. Lev PR, Grodzielski M, Goette NP, et al. Impaired proplatelet formation in immune thrombocytopenia: a novel mechanism contributing to decreased platelet count. Br J Haematol 2014 ; 165 : 854–864. [CrossRef]
  34. Takahashi R, Sekine N, Nakatake T. Influence of monoclonal antiplatelet glycoprotein antibodies on in vitro human megakaryocyte colony formation and proplatelet formation. Blood 1999 ; 93 : 1951–1958. [PubMed]
  35. Larson MK, Watson SP. Regulation of proplatelet formation and platelet release by integrin alpha IIb beta3. Blood 2006 ; 108 : 1509–1514. [CrossRef] [PubMed]
  36. Debili N, Vainchenker W. De macro à micro : l’histoire de la plaquette. Med Sci (Paris) 2008 ; 24 : 467–469. [CrossRef] [EDP Sciences] [PubMed]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.